Excellent
Mostly Aligned
Patient Risk:
Low
Summary
Claims about ONIVYDE-associated severe/life-threatening neutropenia and diarrhea and the key labeled management actions (monitoring, withholding/resuming based on ANC/fever, atropine for early diarrhea, loperamide for late diarrhea, withholding for diarrhea) are consistent with the supplied prescribing information excerpts (Sections 5.1 and 5.2, and supporting dosing context in Sections 2.2/2.3).
Category Scores
Accurate Statements
ONIVYDE can cause severe or life-threatening neutropenia and fatal neutropenic sepsis.
Supported by supplied Section 5.1 label text.
Monitoring complete blood cell counts (on Days 1 and 8 of every cycle) and more frequently if clinically indicated.
Supported by supplied Section 5.1 label text.
Withhold ONIVYDE if ANC is below 1500/mm3 or if neutropenic fever occurs; resume when ANC is 1500/mm3 or above; reduce dose for Grade 3–4 neutropenia or neutropenic fever following recovery in subsequent cycles.
Supported by supplied Section 5.1 label text (with reference to Dosage and Administration 2.2).
ONIVYDE can cause severe and life-threatening diarrhea.
Supported by supplied Section 5.2 label text.
Do not administer ONIVYDE to patients with a bowel obstruction.
Supported by supplied Section 5.2 label text.
There are early-onset and late-onset diarrhea patterns, and an individual patient may experience both.
Supported by supplied Section 5.2 label text.
To reduce risk of severe diarrhea, patients should stop lactose-containing products, eat a low-fat diet, and maintain hydration during treatment.
Supported by supplied Section 5.2 label text.
Withhold ONIVYDE for Grade 2–4 diarrhea; administer intravenous or subcutaneous atropine 0.25 to 1 mg for early onset diarrhea of any severity; initiate loperamide for late onset diarrhea of any severity.
Supported by supplied Section 5.2 label text.
Following recovery to Grade 1 diarrhea, resume ONIVYDE at a reduced dose.
Supported by supplied Section 5.2 label text (reference to Dosage and Administration 2.3).
The provided medical claim(s) regarding neutropenia and diarrhea risks and labeled management actions are explicitly described in the ONIVYDE prescribing information in Sections 5.1 and 5.2.
Supported by the provided label excerpts and the audit narrative summarizing them.
Unsupported Statements
Contradictions
Important Omissions
No evaluation of boxed warnings or contraindications is provided, because none were claimed in the response content.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated content focuses on labeled safety warnings (neutropenia and diarrhea) and corresponding management steps, without adding unlabelled contraindications, dosing errors, or contradictory statements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Suggested Improvement
If future audits include additional claim areas (e.g., boxed warnings, contraindications, drug interactions, special populations), ensure those sections are evaluated against the corresponding label language.